| HORIZON | TRADES | WIN RATE | INSIDER RETURN | SPY RETURN | MEAN EXCESS | MEDIAN EXCESS | T-STAT |
|---|---|---|---|---|---|---|---|
| 7d | 5 | +80.00% | +14.02% | +0.67% | +13.36% | +18.86% | — |
| 14d | 5 | +80.00% | +14.67% | -1.18% | +15.85% | +18.77% | — |
| 30d | 5 | +40.00% | +1.94% | -1.29% | +3.22% | -1.70% | — |
| 60d | 5 | +80.00% | +8.89% | +2.57% | +6.32% | +11.38% | — |
| 90d | 5 | +20.00% | -1.20% | +1.80% | -3.00% | -9.61% | — |
| 180d | 5 | +0.00% | -35.93% | +6.85% | -42.78% | -44.78% | — |
| 1y | 5 | +0.00% | -70.71% | +11.93% | -82.64% | -87.66% | — |
| 2y | 5 | +0.00% | -77.56% | +45.67% | -123.23% | -141.50% | — |
| COMPANY | TYPE | SHARES | PRICE | VALUE | HELD AFTER | TRADE DATE | FILED | DETAILS |
|---|---|---|---|---|---|---|---|---|
| NRXP NRX PHARMACEUTICALS, INC. | PURCHASE CHIEF FINANCIAL OFFICER | 30,000 | $1.10 | $33.0K | 46,337 | Dec 16, 2022 | Dec 18, 2022 ↗ | View → |
| NRXP NRX PHARMACEUTICALS, INC. | PURCHASE CHIEF FINANCIAL OFFICER | 7,021 | $1.11 | $7.8K | 16,337 | Nov 25, 2022 | Dec 18, 2022 ↗ | View → |
| NRXP NRX PHARMACEUTICALS, INC. | PURCHASE CHIEF FINANCIAL OFFICER | 8,716 | $1.12 | $9.8K | 8,716 | Nov 25, 2022 | Dec 18, 2022 ↗ | View → |
| NRXP NRX PHARMACEUTICALS, INC. | PURCHASE CHIEF FINANCIAL OFFICER | 600 | $1.10 | $660 | 9,316 | Nov 25, 2022 | Dec 18, 2022 ↗ | View → |
| NRXP NRX PHARMACEUTICALS, INC. | PURCHASE CHIEF FINANCIAL OFFICER | 600 | $1.10 | $660 | 9,316 | Nov 25, 2022 | Nov 28, 2022 ↗ | View → |
| NRXP NRX PHARMACEUTICALS, INC. | PURCHASE CHIEF FINANCIAL OFFICER | 7,021 | $1.11 | $7.8K | 16,377 | Nov 25, 2022 | Nov 28, 2022 ↗ | View → |
| NRXP NRX PHARMACEUTICALS, INC. | PURCHASE CHIEF FINANCIAL OFFICER | 8,716 | $1.12 | $9.8K | 8,716 | Nov 25, 2022 | Nov 28, 2022 ↗ | View → |
| PDSB PDS BIOTECHNOLOGY CORP | PURCHASE Chief Financial Officer | 17,647 | $8.50 | $150.0K | 17,647 | Jun 15, 2021 | Jun 17, 2021 ↗ | View → |
| PDSB PDS BIOTECHNOLOGY CORP | PURCHASEGRANT Stock grant | 202,800 | — | — | 202,800 | Jan 4, 2021 | Jan 6, 2021 ↗ | View → |
| REFR RESEARCH FRONTIERS INC | PURCHASE CFO & VP-Business Development | 4,661 | $3.11 | $14.5K | 230,454 | Feb 21, 2020 | Feb 24, 2020 ↗ | View → |
| REFR RESEARCH FRONTIERS INC | SALE CFO & VP-Business Development | 30,000 | — | — | 250,191 | Feb 21, 2020 | Feb 24, 2020 ↗ | View → |
| REFR RESEARCH FRONTIERS INC | PURCHASE CFO & VP-Business Development | 5,746 | $2.89 | $16.6K | 225,793 | Feb 21, 2020 | Feb 24, 2020 ↗ | View → |
| REFR RESEARCH FRONTIERS INC | SALE CFO & VP-Business Development | 20,000 | — | — | 150,100 | Feb 21, 2020 | Feb 24, 2020 ↗ | View → |
| REFR RESEARCH FRONTIERS INC | SALE CFO & VP-Business Development | 60,091 | — | — | 190,100 | Feb 21, 2020 | Feb 24, 2020 ↗ | View → |
| REFR RESEARCH FRONTIERS INC | PURCHASE CFO & VP-Business Development | 13,717 | $1.83 | $25.1K | 152,617 | Feb 21, 2020 | Feb 24, 2020 ↗ | View → |
| REFR RESEARCH FRONTIERS INC | SALE CFO & VP-Business Development | 20,000 | — | — | 170,100 | Feb 21, 2020 | Feb 24, 2020 ↗ | View → |
| REFR RESEARCH FRONTIERS INC | PURCHASE CFO & VP-Business Development | 45,272 | $1.00 | $45.3K | 220,047 | Feb 21, 2020 | Feb 24, 2020 ↗ | View → |
| REFR RESEARCH FRONTIERS INC | PURCHASE CFO & VP-Business Development | 22,158 | $1.06 | $23.5K | 174,775 | Feb 21, 2020 | Feb 24, 2020 ↗ | View → |
| REFR RESEARCH FRONTIERS INC | SALE CFO & VP-Business Development | 25,000 | — | — | 280,191 | Feb 21, 2020 | Feb 24, 2020 ↗ | View → |
| REFR RESEARCH FRONTIERS INC | PURCHASEGRANT Stock grant | 20,000 | — | — | 305,191 | Dec 31, 2019 | Jan 2, 2020 ↗ | View → |